Disease Overview：Primary Myelofibrosis（PMF）
Primary myelofibrosis (PMF) is a rare, chronic Philadelphia chromosome-negative myeloproliferative neoplasm characterized by clonal proliferation of abnormal hematopoietic stem cells, progressive bone marrow fibrosis, extramedull cytopenias. Diagnostic criteria include JAK2, CALR, or MPL gene mutations, along with characteristic bone marrow morphology showing reticulin or collagen fibrosis, megakaryocyte atypia, and splenomegaly. Clinical manifestations range from fatigue and constitutional symptoms to anemia, thrombocytopenia, portal hypertension, and increased risk of leukemic transformation. Prognosis varies widely; risk stratification relies on dynamic models such as the MIPSS70+ or GIPSS, incorporating molecular, cytogenetic, and clinical variables. Allogeneic hematopoietic stem cell transplantation remains the only potentially curative option for eligible patients, while JAK inhibitors like ruxolitinib and fedratinib provide symptomatic control and spleen reduction in intermediate- or high-risk disease.
China offers distinct advantages for PMF management: leading hematology centers—such as Peking University People’s Hospital and Ruijin Hospital—host internationally trained specialists with extensive experience in molecular diagnostics, risk-adapted therapy, and transplant protocols. Advanced technologies—including next-generation sequencing, digital pathology, and flow cytometry—are routinely integrated into diagnostic workflows. Over 1,200 allogeneic transplants for myeloid malignancies are performed annually across Tier-1 hospitals, with 3-year overall survival rates exceeding 60% in Treatment costs in China are typically 40–60% lower than in the US or Western Europe, without. As a dedicated medical tourism agency, we facilitate seamless access for international patients: coordinating appointments with certified hematologists, verifying hospital accreditation, providing itemized, transparent pricing, arranging visa support, translation services, and post-treatment follow-up—all tailored to individual clinical and logistical needs.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Primary Myelofibrosis (Hematology Department)
Non-Surgical / Medical Management
*Target criteria:* Asymptomatic low-risk patients (DIPSS-low/intermediate-1), symptomatic intermediate-2/high-risk patients ineligible for transplant, or pre-transplant bridging.
- •JAK Inhibitors (Ruxolitinib/Fedratinib)
- *Monthly drug cost:* $1,850–$2,200 (brand-name ruxolitinib 10 mg BID; fedratinib 400 mg daily) - *Monitoring:* CBC weekly ×4, then monthly ($12–$18/session); LDH, liver function, viral serology ($45–$65/session) - *Annual lab/exam total:* $720–$950
- •Supportive Care
- Transfusion (RBC): $280–$350/unit, plus crossmatch ($40) and iron chelation if needed ($110/month) - Androgen therapy (danazol): $45–$65/month
Surgical / Procedural Interventions
*Eligibility:* Age ≤70 years, DIPSS-high risk, HLA-matched donor available, adequate organ function (cardiac ejection fraction ≥50%, creatinine clearance ≥60 mL/min).
- •Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)
- *Procedure + hospitalization (30-day inpatient):* $42,000–$58,000 (includes conditioning, stem cell infusion, GVHD prophylaxis, ICU days if required) - *Post-transplant monitoring (Day +100):* Chimerism testing ($290), serial PCR for CMV/EBV ($180/test), biopsies as indicated
Special / Complex Condition Options
- •Splenectomy (for refractory cytopenias/symptomatic splenomegaly)
- Laparoscopic procedure + 5-day admission: $8,900–$11,200
- •Clinical Trial Enrollment (Phase II/III JAK2/MPL inhibitor combinations)
Quick Selection Guide
- •Age <55, fit, high-risk: Prioritize allo-HSCT (curative intent; median 5-year OS 55–65%).
- •Age 55–70, comorbidities (COPD, CKD stage 3): Ruxolitinib + transfusion support ($2,500–$3,000/month total) — balances efficacy and safety.
- •Age >70 or frail (ECOG ≥3): Best supportive care only — ESA + transfusions ($1,100–$1,600/month); avoid JAK inhibitors if platelets <50×10⁹/L.
- •Budget-constrained (<$1,000/month): Generic danazol + intermittent transfusions; monitor for iron overload.
- •Massive splenomegaly with portal hypertension: Splenectomy preferred over indefinite JAK inhibition if surgical risk acceptable (MELD <10).
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Primary Myelofibrosis Medical Vacation Packages
Curated transparent all-inclusive packages combining Primary Myelofibrosis treatment with China top medical destinations:
